UNICYCIVE THERAPEUTICS
Unicycive Therapeutics provides development programs that focus on treating kidney diseases with significant unmet medical needs. It aims to open the way for a broad range of disease-modifying therapies by modifying the intracellular and extracellular concentrations of these various electrolytes and ions in Chronic Kidney Disease and Gitelman’s Syndrome and by addressing the underlying mitochondrial pathology and inflammation associated with Acute Kidney Disease. Unicycive Therapeutics was founded in 2016 and is headquartered in Los Altos, California.
UNICYCIVE THERAPEUTICS
Industry:
Biotechnology Health Care Health Diagnostics Medical
Founded:
2016-01-01
Address:
Los Altos, California, United States
Country:
United States
Website Url:
http://www.unicycive.com
Total Employee:
11+
Status:
Active
Contact:
(650) 384-0642
Total Funding:
86.6 M USD
Technology used in webpage:
Amazon HSTS Amazon Virginia Region CloudFront PostalAddress Schema Amazon S3 COVID-19 Amazon S3 CDN Vimeo Corporation Schema
Similar Organizations
ArtisanBio
ArtisanBio is provider of cell engineering and data analysis solutions that advance the cell therapy revolution.
Eikon Therapeutics
Eikon Therapeutics is a biopharmaceutical company that develops live-cell resolution microscopy and engineering for drug discovery.
Eden Biologics
Eden Biologics is a biopharmaceutical company that develops biosimilars and accelerates the development programs for clients & partners.
Prolocor
Prolocor is a biotechnology company that develops diagnostic tests for cardiovascular diseases.
Thrive Earlier Detection
Thrive Earlier Detection is a healthcare company that integrates earlier cancer detection into routine medical care.
Trevarx Biomedical
Trevarx Biomedical is a biomedical startup that develops new radiopharmaceuticals.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Great Point Partners
Great Point Partners investment in Post-IPO Equity - Unicycive Therapeutics
Velan Capital
Velan Capital investment in Post-IPO Equity - Unicycive Therapeutics
Vivo Capital
Vivo Capital investment in Post-IPO Equity - Unicycive Therapeutics
Octagon Capital Advisors
Octagon Capital Advisors investment in Post-IPO Equity - Unicycive Therapeutics
Logos Capital
Logos Capital investment in Post-IPO Equity - Unicycive Therapeutics
SilverArc Capital
SilverArc Capital investment in Post-IPO Equity - Unicycive Therapeutics
Walleye Capital
Walleye Capital investment in Post-IPO Equity - Unicycive Therapeutics
Nantahala Capital Management
Nantahala Capital Management investment in Post-IPO Equity - Unicycive Therapeutics
Logos Capital
Logos Capital investment in Post-IPO Equity - Unicycive Therapeutics
RA Capital Management
RA Capital Management investment in Post-IPO Equity - Unicycive Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2021-10-26 | Unicycive Therapeutics Appoints Douglas Jermasek As Executive Vice President, Corporate Strategy |
Official Site Inspections
http://www.unicycive.com Semrush global rank: 5.21 M Semrush visits lastest month: 1.49 K
- Host name: 141.193.213.10
- IP address: 141.193.213.10
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Unicycive Therapeutics"
Company - Unicycive
UNICYCIVE was founded in August 2016 by Shalabh Gupta, MD, with the goal of building a company to solve the most pressing unmet medical needs in renal diseases. In 2018, Dr. …See details»
Unicycive Therapeutics Inc. – Small enough to make a huge …
Small enough to make a huge difference Bigger doesn’t always mean better. At Unicycive, our small but mighty team is driving outsized opportunity while solving for the most pressing unmet …See details»
Investor Relations :: Unicycive Therapeutics, Inc. (UNCY)
Mar 31, 2025 Company Unicycive Therapeutics, Inc. 4300 El Camino Real Suite 210 Los Altos, CA 94022 T: 650-351-4495 [email protected]See details»
Unicycive Therapeutics - LinkedIn
Unicycive Therapeutics invent and develop medications that help kidney patients feel their best and enjoy the best possible quality of life.See details»
Unicycive Announces $50 Million Private Placement
Mar 14, 2024 Unicycive has agreed to file a registration statement with the Securities and Exchange Commission registering the resale of the shares of common stock issued in this …See details»
Unicycive Therapeutics - Crunchbase Company Profile & Funding
Unicycive Therapeutics provides development programs that focus on treating kidney diseases with unmet medical needs.See details»
Unicycive Therapeutics, Inc. - AnnualReports.com
Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug candidate, oxylanthanum carbonate (OLC), is a novel …See details»
Unicycive Therapeutics, Inc. (UNCY) - Yahoo Finance
See the company profile for Unicycive Therapeutics, Inc. (UNCY) including business summary, industry/sector information, number of employees, business summary, corporate governance, …See details»
Investor Relations :: Unicycive Therapeutics, Inc. (UNCY)
We are a biotechnology company dedicated to developing treatments for certain medical conditions. Currently, we have two programs focused on kidney disease that we believe have …See details»
Unicycive Therapeutics - Contacts, Employees, Board Members, …
Unicycive Therapeutics has 2 current employee profiles, including Founder & CEO Shalabh Gupta. Unicycive Therapeutics has 2 board members and advisors, including Dominic Marasco.See details»
Unicycive Announces up to $130 Million Financing to …
Mar 6, 2023 Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug, Renazorb, is a novel investigational phosphate …See details»
Video: About Unicycive - Unicycive
Hear from our CEO, Dr. Shalabh Gupta, about why we wanted to build a company that was focused on addressing nephrology kidney diseases.See details»
Unicycive Presents New Patient-Level Data Underscoring …
Apr 10, 2025 – Patient-reported outcomes from Phase 2 trial of oxylanthanum carbonate (OLC) demonstrate high patient satisfaction with OLC compared to their prior phosphate lowering …See details»
Unicycive Therapeutics Announces Initial Positive Patient ... - Nasdaq
Jul 10, 2024 --Unicycive Therapeutics, Inc., a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced the initial results from the patient …See details»
Unicycive Therapeutics, Inc. (UNCY) - Yahoo Finance
See the company profile for Unicycive Therapeutics, Inc. (UNCY) including business summary, industry/sector information, number of employees, business summary, corporate governance, …See details»
Unicycive 2025 Company Profile: Stock Performance & Earnings
Information on stock, financials, earnings, subsidiaries, investors, and executives for Unicycive. Use the PitchBook Platform to explore the full profile.See details»
News :: Unicycive Therapeutics, Inc. (UNCY)
Feb 20, 2025 Unicycive Therapeutics Announces the Publication of Preclinical Data on Synergies Between Oxylanthanum Carbonate and Tenapanor in American Society of …See details»
Unicycive Therapeutics - Overview, News & Similar companies
View Unicycive Therapeutics (www.unicycive.com) location in California, United States , revenue, industry and description. Find related and similar companies as well as employees by title and …See details»
Pipeline - Unicycive
Unicycive's (UNCY) meticulously designed biotech system & end-to-end mining process allow us to deliver disease-modifying therapies quickly & efficiently.See details»
Unicycive Therapeutics Announces Publication of Oxylanthanum …
Dec 17, 2024 About Unicycive Therapeutics Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug candidate, …See details»